Ordinary shares, $0.01 par value
- Symbol
- ALKS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Alkermes plc
ALKSNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operatio ns and Financial Condition. On November 3, 2026, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2026.…
Press release in this filing
Alkermes plc Reports Third Quarter 2026 Financial Results →Company context
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes has established a leadership position in orexin biology and is advancing a portfolio of investigational orexin 2 receptor agonists for narcolepsy, idiopathic hypersomnia and other psychiatric and neurological disorders, including attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Current securities
Recent company filings
Registered securities in this filing
Alkermes plc. · 8-K · Filed 2026-11-03
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operatio
ns and Financial Condition.
On November 3, 2026, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2026. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on November 3, 2026 discussing such financial results are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (2)
Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2026 Financial Results - Third Quarter Revenues of $480.1 Million - - GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million - - Company Reiterates 2026 Financial Expectations - DUBLIN, Nov. 3, 2026 - Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026. “We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder, further strengthens our leadership position in orexin-based research. As we continue to advance our orexin development portfolio, we are growing the body of evidence supporting the potential of orexin biology across mul…
Open exhibit ↗Third Quarter 2026 Financial Results & Business Update November 3, 2026 Exhibit 99.2 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc’s (the “Company”) expectations with respect to its current and future financial, commercial and operating performance, business plans or prospects, including expected revenue and profitability. The Company cautions that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: the Company may not be able to achieve its financial expectations, including those related to revenue and profitability; the Company’s commercial activities may not result in the benefits that the Company anticipates; the unfavorable outcome of arbitration, litigation, including so-called “Parag…
Open exhibit ↗